BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. ACN
4. IBM
5. PRIM
6. META
7. DPZ
8. N2EW34
9. INTC
10. IMNN

Go back to BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
(NASDAQ: BBIO) Delayed: 68.92 --0 (-0%)
Previous Close $68.92    52 Week High $ 
Open $68.92    52 Week Low $ 
Day High $68.92    P/E N/A 
Day Low $68.92    EPS $ 
Volume 214